Addressing car-t reimbursement challenges in US healthcare
There has been much discussion and debate about whether provider reimbursement rates for chimeric antigen receptor T-cell (CAR-T) therapies are adequate. This analysis clarifies common misconceptions, examining the realities of the current car-t reimbursement landscape. For more info: https://www.zs.com/insights/ca....r-t-reimbursement-in